Piramal Pharma expands into paediatric critical care with UK approval for Neoatricon
Piramal Pharma’s Neoatricon secures UK approval, revolutionizing paediatric critical care. Learn how this breakthrough will reshape neonatal hypotension treatment. Read More
Vertex Pharmaceuticals bags UK approval for ALYFTREK, a next-generation cystic fibrosis treatment
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor), a next-generation CFTR modulator treatment developed by Vertex Pharmaceuticals ... Read More
MeiraGTx’s rAAV8.hRKp.AIPL1 shows remarkable efficacy in treating severe retinal dystrophy
A gene therapy developed by MeiraGTx Holdings plc has demonstrated remarkable success in restoring vision to children born blind due to severe retinal dystrophy. The ... Read More
MeiraGTx’s gene therapy trial shows transformative results for children with LCA4 retinal dystrophy
MeiraGTx Holdings plc has announced groundbreaking results from its gene therapy trial targeting Leber congenital amaurosis 4 (LCA4), a severe and rare form of retinal ... Read More
Dr. Reddy’s Laboratories secures key European endorsement for Rituximab biosimilar
In a significant development for the pharmaceutical industry, Dr. Reddy’s Laboratories Ltd. has received a positive opinion from the European Medicines Agency’s (EMA) Committee for ... Read More
UK MHRA approves first generic raltegravir medicines for HIV treatment
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for the first generic raltegravir medicines, designed to treat adult and pediatric HIV ... Read More
Mundipharma’s rezafungin cleared by MHRA for invasive candidiasis in Great Britain
In a significant advancement for antifungal therapy, Napp Pharmaceuticals Limited, a key player within the international network of Mundipharma independent associated companies, has announced the ... Read More
UK grants emergency authorization for Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted emergency use authorization (EUA) for the BNT162b2 Covid-19 vaccine candidate, developed by Pfizer and ... Read More